Literature DB >> 6851037

Reduction in infarct size, arrhythmias and chest pain by early intravenous beta blockade in suspected acute myocardial infarction.

S Yusuf, P Sleight, P Rossi, D Ramsdale, R Peto, L Furze, H Sterry, M Pearson, R Motwani, S Parish, R Gray, D Bennett, C Bray.   

Abstract

Four hundred seventy-seven patients suspected of having had acute myocardial infarction within less than 12 hours were randomized to receive i.v. atenolol followed by oral treatment for 10 days or to a control group. In patients with ECG changes indicative of infarction at entry, i.v. atenolol significantly reduced enzyme release by one-third and enhanced R-wave preservation. In patients without such ECG changes, treatment significantly prevented the development of infarction in a proportion of patients. There was also a significant reduction in R-on-T ectopics, repetitive ventricular arrhythmias and supraventricular arrhythmias. Treated patients had significantly greater pain relief and required fewer opiate analgesics. Significantly fewer atenolol-treated patients died by 10 days (the treatment period), had nonfatal cardiac arrests, developed heart failure, or suffered reinfarction.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6851037

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  17 in total

Review 1.  Choosing the right beta-blocker. A guide to selection.

Authors:  J R Hampton
Journal:  Drugs       Date:  1994-10       Impact factor: 9.546

Review 2.  According to MIAMI and ISIS-I trials, can a general recommendation be given for beta blockers in acute myocardial infarction?

Authors:  J K Kjekshus
Journal:  Cardiovasc Drugs Ther       Date:  1988-05       Impact factor: 3.727

Review 3.  Atenolol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders.

Authors:  A N Wadworth; D Murdoch; R N Brogden
Journal:  Drugs       Date:  1991-09       Impact factor: 9.546

4.  Early intravenous beta-blockers in patients with acute coronary syndrome--a meta-analysis of randomized trials.

Authors:  Saurav Chatterjee; Debanik Chaudhuri; Rajesh Vedanthan; Valentin Fuster; Borja Ibanez; Sripal Bangalore; Debabrata Mukherjee
Journal:  Int J Cardiol       Date:  2012-11-17       Impact factor: 4.164

5.  Limitation of myocardial infarct size. Present status.

Authors:  S Yusuf; P Sleight
Journal:  Drugs       Date:  1983-05       Impact factor: 9.546

Review 6.  The potential for added benefits with beta-blockers and calcium antagonists in treating cardiovascular disorders.

Authors:  W G Nayler
Journal:  Drugs       Date:  1988       Impact factor: 9.546

Review 7.  Beta-adrenoceptor blockers. An update on their role in acute myocardial infarction.

Authors:  R M Norris
Journal:  Drugs       Date:  1985-02       Impact factor: 9.546

8.  Effect of the ultrashort-acting beta-blocker Brevibloc on free-radical-mediated injuries during the early reperfusion state.

Authors:  E Röth; B Török
Journal:  Basic Res Cardiol       Date:  1991 Sep-Oct       Impact factor: 17.165

9.  Effect of adrenaline on myocardial oxygen consumption during selective and non-selective beta-adrenoceptor blockade comparison of atenolol and pindolol.

Authors:  H Ihlen; S Simonsen; D Welzel
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

Review 10.  Nitrates for unstable angina.

Authors:  U Thadani; L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1994-10       Impact factor: 3.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.